Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity
- PMID: 12794305
- DOI: 10.1385/JMN:20:2:115
Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity
Abstract
The Cholecystokinin type 1 and type 2 receptors (CCK-1R and CCK-2R) share >50% amino acid identity, as well as subnanomolar affinity for the endogenous peptide cholecystokinin octapeptide (CCK-8). Although it is likely that these two receptor subtypes share amino acids that confer CCK-8 affinity, it has been difficult to identify such residues. We have examined the role of several transmembrane domain (TMD) IV residues that are common to both CCK receptor subtypes. In both the CCK-1R and CCK-2R, we demonstrate that alanine substitution of two TMD IV residues, which are highly conserved among all known CCK receptor subtypes and species homologs, significantly decrease CCK-8 affinity. Despite the observed decrease in peptide binding, the mutant receptors maintain close to wild-type affinity for the respective subtype selective nonpeptide ligands, 3H-labeled L-364,714 (CCK-1R) and 3H-labeled L-365,260 (CCK-2R), suggesting conserved tertiary structure of these mutants. Assessment of CCK-8-induced inositol phosphate production at each of the mutant CCK receptors revealed normal peptide efficacy. In contrast, peptide potencies are reduced in parallel with the observed decreases in affinity. Taken together, these findings suggest that important peptide affinity determinants are localized on TMD IV, a region that has not previously been considered a major contributor to ligand affinity in either CCK receptors or other G protein-coupled peptide receptors.
Similar articles
-
CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.Mol Pharmacol. 2000 Aug;58(2):399-406. doi: 10.1124/mol.58.2.399. Mol Pharmacol. 2000. PMID: 10908308
-
Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.Mol Pharmacol. 1998 Nov;54(5):857-63. doi: 10.1124/mol.54.5.857. Mol Pharmacol. 1998. PMID: 9804620
-
Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.Protein Sci. 1999 Nov;8(11):2347-54. doi: 10.1110/ps.8.11.2347. Protein Sci. 1999. PMID: 10595537 Free PMC article.
-
Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.Regul Pept. 2008 Jan 10;145(1-3):17-23. doi: 10.1016/j.regpep.2007.09.024. Epub 2007 Sep 25. Regul Pept. 2008. PMID: 17961734 Review.
-
Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology.Ann N Y Acad Sci. 1994 Mar 23;713:11-21. doi: 10.1111/j.1749-6632.1994.tb44047.x. Ann N Y Acad Sci. 1994. PMID: 7514372 Review.
Cited by
-
Peptides complementary to the active loop of porin P2 from Haemophilus influenzae modulate its activity.Int J Nanomedicine. 2012;7:2361-71. doi: 10.2147/IJN.S30467. Epub 2012 May 11. Int J Nanomedicine. 2012. PMID: 22654515 Free PMC article.
-
Cholecystokinin receptors in Atlantic salmon: molecular cloning, gene expression, and structural basis.Physiol Rep. 2013 Oct;1(5):e00069. doi: 10.1002/phy2.69. Epub 2013 Oct 2. Physiol Rep. 2013. PMID: 24303160 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources